Abstract
Aim: To correlate the baseline and change of chromogranin A (CgA) levels with patient survival and tumor response in Asian patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Patients and Methods: Sixty patients with advanced GEP-NET treated in a medical center between April 2010 and April 2013 were enrolled retrospectively. Plasma CgA level was analyzed for correlation with the patient's clinical outcome and tumor response. Results: Multivariate analysis showed that independent favorable prognostic factors for overall survival were: Eastern Cooperative Oncology Groups performance score 0-1, World Health Organization tumor grade 1-2, single organ metastasis and less than twice the upper normal range of baseline CgA levels. Percentage changes in paired CgA tests (ΔCgA) of more than 17% can predict partial response or stable disease from progressive disease with 91.2% sensitivity and 82.9% specificity. Conclusion: Baseline plasma CgA levels predicted overall survival and ΔCgA predicted treatment response in Asian patients with GEP-NETs.
| Original language | English |
|---|---|
| Pages (from-to) | 5661-5669 |
| Number of pages | 9 |
| Journal | Anticancer Research |
| Volume | 34 |
| Issue number | 10 |
| State | Published - 01 10 2014 |
Bibliographical note
Publisher Copyright:© 2014, International Institute of Anticancer Research. All rights reserved.
Keywords
- Biomarker
- Chromogranin A
- Gastroenteropancreatic.
- Neuroendocrine tumor
- Tumor response
